Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome

被引:24
|
作者
Jonker, L. A. [1 ]
Lebbink, C. A. [1 ,2 ]
Jongmans, M. C. J. [2 ,3 ]
Nievelstein, R. A. J. [2 ,4 ]
Merks, J. H. M. [2 ]
Nieveen van Dijkum, E. J. M. [5 ]
Links, T. P. [6 ]
Hoogerbrugge, N. [7 ]
van Trotsenburg, A. S. P. [8 ]
van Santen, H. M. [1 ,2 ]
机构
[1] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Endocrinol, POB 85090, NL-3508 AB Utrecht, Netherlands
[2] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Genet, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Radiol & Nucl Med, Utrecht, Netherlands
[5] Univ Amsterdam, Med Ctr, Dept Surg, Canc Ctr Amsterdam, Amsterdam, Netherlands
[6] Univ Med Ctr Groningen, Dept Endocrinol, Groningen, Netherlands
[7] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands
[8] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Endocrinol, Med Ctr, Amsterdam, Netherlands
关键词
Differentiated thyroid carcinoma; PTEN hamartoma tumor syndrome; pediatric; Thyroid carcinoma surveillance program; Thyroid cancer genetics; COWDEN SYNDROME; GERMLINE PTEN; PHOSPHATIDYLINOSITOL; 3-KINASE/AKT; CANCER; RISK; INDIVIDUALS; ADOLESCENTS; DISEASE;
D O I
10.1159/000508872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:PTEN hamartoma tumor syndrome (PHTS) represents a group of syndromes caused by a mutation in thePTENgene. Children with a germlinePTENmutation have an increased risk of developing differentiated thyroid carcinoma (DTC). Several guidelines have focused on thyroid surveillance in these children, but studies substantiating these recommendations are lacking.Objective:The present study intends to provide the available evidence for a thyroid carcinoma surveillance program in children with PHTS.Methods:An extensive literature search was performed to identify all studies on DTC in pediatric PHTS patients. Two pediatric cases are presented to illustrate the pros and cons of thyroid carcinoma surveillance. Recommendations for other patient groups at risk for DTC were evaluated. Consensus within the study team on recommendations for children with PHTS was reached by balancing the incidence and behavior of DTC with the pros and cons of thyroid surveillance, and the different surveillance methods.Results:In 5 cohort studies the incidence of DTC in childhood ranged from 4 to 12%. In total 57 cases of DTC and/or benign nodular disease in pediatric PHTS patients were identified, of which 27 had proven DTC, with a median age of 12 years (range 4-17). Follicular thyroid carcinoma (FTC) was diagnosed in 52% of the pediatric DTC patients. No evidence was found for a different clinical behavior of DTC in PHTS patients compared to sporadic DTC.Conclusions:Children with PHTS are at increased risk for developing DTC, with 4 years being the youngest age reported at presentation and FTC being overrepresented. DTC in pediatric PHTS patients does not seem to be more aggressive than sporadic DTC.Recommendations:Surveillance for DTC in pediatric PHTS patients seems justified, as early diagnosis may decrease morbidity. Consensus within the study team was reached to recommend surveillance from the age of 10 years onwards, since at that age the incidence of DTC seems to reach 5%. Surveillance for DTC should consist of yearly neck palpation and triennial thyroid ultrasound. Surveillance in children with PHTS should be performed in a center of excellence for pediatric thyroid disease or PHTS.
引用
收藏
页码:234 / 242
页数:9
相关论文
共 50 条
  • [21] Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex
    Schultz, Kris Ann P.
    Macfarland, Suzanne P.
    Perrino, Melissa R.
    Mitchell, Sarah G.
    Kamihara, Junne
    Nelson, Alexander T.
    Mallinger, Paige H. R.
    Brzezinski, Jack J.
    Maxwell, Kara N.
    Woodward, Emma R.
    Gallinger, Bailey
    Kim, Sun Young
    Greer, Mary-Louise C.
    Schneider, Kami Wolfe
    Scollon, Sarah R.
    Das, Anirban
    Wasserman, Jonathan D.
    Eng, Charis
    Malkin, David
    Foulkes, William D.
    Michaeli, Orli
    Bauer, Andrew J.
    Stewart, Douglas R.
    CLINICAL CANCER RESEARCH, 2025, 31 (02) : 234 - 244
  • [22] The microbiome in PTEN hamartoma tumor syndrome
    Byrd, Victoria
    Getz, Ted
    Padmanabhan, Roshan
    Arora, Hans
    Eng, Charis
    ENDOCRINE-RELATED CANCER, 2018, 25 (03) : 233 - 243
  • [23] PTEN hamartoma tumor syndrome: Clinical risk assessment and management protocol
    Ngeow, Joanne
    Eng, Charis
    METHODS, 2015, 77-78 : 11 - 19
  • [24] Extended spectrum of cancers in PTEN hamartoma tumor syndrome
    Yehia, Lamis
    Plitt, Gilman
    Tushar, Ann M.
    Liu, Darren
    Joo, Julia
    Ni, Ying
    Patil, Sujata
    Eng, Charis
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [25] Gingival Overgrowths Revealing PTEN Hamartoma Tumor Syndrome: Report of Novel PTEN Pathogenic Variants
    Sutera, Samuele
    Giachino, Daniela Francesca
    Pelle, Alessandra
    Zuntini, Roberta
    Pentenero, Monica
    BIOMEDICINES, 2023, 11 (01)
  • [26] SHH medulloblastoma and very early onset of bowel polyps in a child with PTEN hamartoma tumor syndrome
    Caroleo, Anna Maria
    Rotulo, Silvia
    Agolini, Emanuele
    Macchiaiolo, Marina
    Boccuto, Luigi
    Antonelli, Manila
    Colafati, Giovanna Stefania
    Cacchione, Antonella
    Megaro, Giacomina
    Carai, Andrea
    De Ioris, Maria Antonietta
    Lodi, Mariachiara
    Tornesello, Assunta
    Simone, Valeria
    Torroni, Filippo
    Cinalli, Giuseppe
    Mastronuzzi, Angela
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2023, 16
  • [27] Thyroid findings in pediatric and adult patients with PTEN hamartoma tumor syndrome: A retrospective analysis, and literature review
    Milani, Donatella
    Dolci, Alessia
    Muller, Ilaria
    Pavesi, Maria Angela
    Runza, Letterio
    Kuhn, Elisabetta
    Natacci, Federica
    Peissel, Bernard
    Ricci, Maria Teresa
    Despini, Luca
    Tomasello, Gianluca
    Grossi, Francesco
    Garrone, Ornella
    Gambini, Donatella
    ENDOCRINE, 2023, 81 (01) : 98 - 106
  • [28] A review on age-related cancer risks in PTEN hamartoma tumor syndrome
    Hendricks, Linda A. J.
    Hoogerbrugge, Nicoline
    Schuurs-Hoeijmakers, Janneke H. M.
    Vos, Janet R.
    CLINICAL GENETICS, 2021, 99 (02) : 219 - 225
  • [29] Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome
    Mester, Jessica
    Eng, Charis
    GENETICS IN MEDICINE, 2012, 14 (09) : 819 - 822
  • [30] The PTEN Hamartoma Tumor Syndrome: How Oral Clinicians May Save Lives
    Fardal, Oystein
    Nevland, Kristian
    Johannessen, Anne Christine
    Vetti, Hildegunn Hoberg
    CLINICAL ADVANCES IN PERIODONTICS, 2023, 13 (01) : 21 - 26